Cancer Family
Malignant Breast Neoplasm
CI-CAN-00000227Explore in graph →
Top-level2,628 active trials43 approved drugs310 evidence items
- NCIt
- C9335
- ICD-10
- C50
- DOID
- 1612
- Other
- 2 more codes
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000227Explore in graph →
Clinical trials
12,359 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,368)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04084730 | Study of 3-Day Partial Breast Radiation Therapy in Women With Breast Cancer | recruiting | Phase 2 | 280 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT04644068 | Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies(PETRA) | active not recruiting | Phase 1 / Phase 2 | 702 | AstraZenecaINDUSTRY | 14 | Sep 21, 2026 |
| clinicaltrials |
| NCT04734262 | A Phase II Study to Explore the Safety, Tolerability, and Preliminary Antitumor Activity of Sitravatinib Plus Tislelizumab or Combination With Nab-paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)(SPARK) | active not recruiting | Phase 2 | 98 | Fudan UniversityOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT05550415 | The Role of Simvastatin in The Epithelial-Mesenchymal Transition Process of Breast Cancer | recruiting | Phase 2 | 26 | Universitas IndonesiaOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT01334021 | Genetic Testing in Predicting Tumor Response in Patients With Stage I-III HER2 Negative Invasive Breast Cancer | active not recruiting | Phase 2 | 1,100 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT01872260 | Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer | active not recruiting | Phase 1 / Phase 2 | 259 | Novartis PharmaceuticalsINDUSTRY | 8 | Sep 18, 2026 | clinicaltrials |
| NCT04090398 | Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer That Has Spread to the Bones | active not recruiting | Phase 2 | 70 | National Cancer Institute (NCI)NIH | 1 | Sep 18, 2026 | clinicaltrials |
| NCT04524000 | Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer | active not recruiting | Phase 2 | 24 | Novartis PharmaceuticalsINDUSTRY | 1 | Sep 18, 2026 | clinicaltrials |
| NCT07340541 | Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies(EVOLVE-BDT) | recruiting | Phase 2 | 700 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT00417495 | Sentinel Lymph Node Technique in Multifocal Breast Cancer(IGASSU) | completed | Phase 2 | 216 | Centre Oscar LambretOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT01658462 | Phase II Study of Docetaxel +/- Nintedanib in Breast Cancer(VAROCE) | completed | Phase 2 | 51 | Centre Oscar LambretOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT04152499 | Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)(MK-2870-001) | active not recruiting | Phase 1 / Phase 2 | 1,410 | Klus Pharma Inc.INDUSTRY | 6 | Sep 17, 2026 | clinicaltrials |
| NCT07109726 | A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations | recruiting | Phase 1 / Phase 2 | 205 | Terremoto Biosciences Inc.INDUSTRY | 4 | Sep 17, 2026 | clinicaltrials |
| NCT07685938 | Pharmacologic Therapies to Mitigate Radiation- Associated Heart Disease | recruiting | Phase 2 | 60 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07825454 | Pilot Study of Hydroxychloroquine for the Treatment of AIMSS(AIMSS) | not yet recruiting | Phase 2 | 35 | Indiana UniversityOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07826052 | Chemotherapy Exemption in Elderly Women With Node-Positive ER+/HER2- Breast Cancer(ELDER) | not yet recruiting | Phase 2 | 494 | Fudan UniversityOTHER | 0 | Sep 17, 2026 | clinicaltrials |
| NCT03624543 | CFI-400945 in Patients With Advanced/Metastatic Breast Cancer | active not recruiting | Phase 2 | 51 | Canadian Cancer Trials GroupNETWORK | 1 | Sep 16, 2026 | clinicaltrials |
| NCT04273061 | Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity(CAPTIV-8) | recruiting | Phase 2 | 50 | British Columbia Cancer AgencyOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT05165225 | Phase II Neoadjuvant Pyrotinib Combined With Neoadjuvant Chemotherapy in HER2-low-expressing and HR Positive Early or Locally Advanced Breast Cancer: a Single-arm, Non-randomized, Single-center, Open Label Trial | active not recruiting | Phase 2 | 48 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT05751668 | Finding an Effective Dose of GM1 to Reduce or Prevent Neuropathy (Numbness or Weakness) Due to Treatment With Paclitaxel (Phase II) | active not recruiting | Phase 2 | 7 | Alliance for Clinical Trials in OncologyOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT06324357 | Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread | recruiting | Phase 1 / Phase 2 | 768 | Boehringer IngelheimINDUSTRY | 10 | Sep 16, 2026 | clinicaltrials |
| NCT06353997 | Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC Patients | recruiting | Phase 2 | 12 | Providence Health & ServicesOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT07748208 | A Study Evaluating the Safety of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With Advanced Breast Cancer (ABC) and Type 2 Diabetes | not yet recruiting | Phase 2 | 40 | Hoffmann-La RocheINDUSTRY | 0 | Sep 16, 2026 | clinicaltrials |
| NCT04585750 | The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) | recruiting | Phase 1 / Phase 2 | 300 | PMV Pharmaceuticals, IncINDUSTRY | 9 | Sep 15, 2026 | clinicaltrials |
| NCT05115474 | Study of Screening Brain MRIs in Stage IV Breast Cancer | recruiting | Phase 2 | 170 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07341737 | SL-28 for Advanced Solid Tumours | recruiting | Phase 1 / Phase 2 | 60 | Second Life TherapeuticsINDUSTRY | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07686250 | Evaluation and Outcomes of SAVI Scout MD for Localized Breast Surgery | recruiting | Phase 2 | 37 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07702292 | [68Ga]BED003 PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications | recruiting | Phase 2 | 71 | Blue Earth DiagnosticsINDUSTRY | 2 | Sep 15, 2026 | clinicaltrials |
| NCT07743723 | A Study of IOV-5001 in Adults With Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 106 | Iovance Biotherapeutics, Inc.INDUSTRY | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07796880 | Neoadjuvant Culmerciclib Combined With Endocrine Therapy for Hormone Receptor-Positive， Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer | recruiting | Phase 2 | 80 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT03077841 | Hypofractionated Partial Breast Irradiation in Treating Patients With Early Stage Breast Cancer | suspended | Phase 2 / Phase 3 | 928 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT03359954 | Radiation Therapy Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative Breast Cancer | active not recruiting | Phase 2 | 25 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT04090567 | Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer | recruiting | Phase 2 | 60 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT04140526 | Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC(PRESERVE-001) | active not recruiting | Phase 1 / Phase 2 | 733 | OncoC4, Inc.INDUSTRY | 2 | Sep 14, 2026 | clinicaltrials |
| NCT04191135 | Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009) | terminated | Phase 2 | 462 | Merck Sharp & Dohme LLCINDUSTRY | 15 | Sep 14, 2026 | clinicaltrials |
| NCT04266249 | CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy | active not recruiting | Phase 2 | 2,175 | ECOG-ACRIN Cancer Research GroupNETWORK | 2 | Sep 14, 2026 | clinicaltrials |
| NCT04316117 | Using FDG-PET/CT to Assess Response of Bone-Dominant Metastatic Breast Cancer, FEATURE Study | active not recruiting | Phase 2 | 138 | ECOG-ACRIN Cancer Research GroupNETWORK | 3 | Sep 14, 2026 | clinicaltrials |
| NCT05262400 | A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 235 | PfizerINDUSTRY | 9 | Sep 14, 2026 | clinicaltrials |
| NCT05710328 | Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT Trial | active not recruiting | Phase 2 | 235 | ECOG-ACRIN Cancer Research GroupNETWORK | 2 | Sep 14, 2026 | clinicaltrials |
| NCT07678957 | A Study Comparing BL-M07D1 With DS-8201 in Patients With HR-Positive, HER2-Low Expressing Recurrent/Metastatic Breast Cancer | recruiting | Phase 2 | 120 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 14, 2026 | clinicaltrials |
| NCT03147287 | Palbociclib After CDK and Endocrine Therapy (PACE) | active not recruiting | Phase 2 | 220 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT04191499 | A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer(INAVO120) | active not recruiting | Phase 2 / Phase 3 | 325 | Hoffmann-La RocheINDUSTRY | 28 | Sep 11, 2026 | clinicaltrials |
| NCT05123482 | A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies | recruiting | Phase 1 / Phase 2 | 460 | AstraZenecaINDUSTRY | 15 | Sep 11, 2026 | clinicaltrials |
| NCT05130801 | A Study of Multiparametric MRI and pHLIP® ICG in Breast Cancer Imaging During Surgery | recruiting | Phase 1 / Phase 2 | 55 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT05306041 | Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast Cancer(GeparPiPPa) | recruiting | Phase 2 | 170 | GBG Forschungs GmbHOTHER | 6 | Sep 11, 2026 | clinicaltrials |
| NCT06033092 | Low Dose TamOxifen and LifestylE Changes for bReast cANcer prevenTion(TOLERANT) | completed | Phase 2 | 110 | European Institute of OncologyOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT06247995 | A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.(NeoB-Cap1) | active not recruiting | Phase 1 / Phase 2 | 20 | Novartis PharmaceuticalsINDUSTRY | 11 | Sep 11, 2026 | clinicaltrials |
| NCT03424005 | A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer(Morpheus-panBC) | recruiting | Phase 1 / Phase 2 | 1,132 | Hoffmann-La RocheINDUSTRY | 9 | Sep 10, 2026 | clinicaltrials |
| NCT03964532 | TALAVE: Induction Talazoparib Followed by Combination of Talazoparib and Avelumab in Advanced Breast Cancer | active not recruiting | Phase 1 / Phase 2 | 24 | Georgetown UniversityOTHER | 1 | Sep 10, 2026 | clinicaltrials |
Data updated 4 days agoSource updated Sep 21, 2026source: clinicaltrials